---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-049338"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:46:45.957587+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology ships first international order of LYMPHIR to Europe

## Summary
- First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.
- Product will be available via Named Patient Programs under applicable local regulations.
- LYMPHIR approved by FDA in August 2024 for relapsed/refractory CTCL; U.S. commercial launch in December 2025.
- Citius Oncology (Nasdaq: CTOR) is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).
- International expansion complements ongoing U.S. launch progress with formulary access and payer coverage.

## SEC filing metadata
- accession: 0001213900-26-049338
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/0001213900-26-049338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/ea0288203-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-049338
- JSON: https://secwatch.observer/filing/0001213900-26-049338.json
- Plain text: https://secwatch.observer/filing/0001213900-26-049338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.